Thu, Jul 24, 2014, 7:59 PM EDT - U.S. Markets closed

Recent

% | $
Click the to save as a favorite.

Curis, Inc. Message Board

  • samsonisis samsonisis Oct 6, 2013 4:12 PM Flag

    Pink Sheets Daily - October 3, 2013

    Curis Propels Two Proprietary Drugs Forward In Plan To Retain Value

    Cancer drug developer Curis held its first R&D day Oct. 3, a sign its early pipeline is maturing. The company
    outlined development plans for two proprietary drugs, an IAP inhibitor and a PI3K/HDAC inhibitor, both in early
    clinical development. As for partnering those assets, CEO Passeri said the company is looking to retain more
    value for them than it did for Erivedge.

    Sentiment: Strong Buy

 
CRIS
1.79+0.01(+0.56%)Jul 24 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.